Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

A process is presented where a feed stream containing a hydrogen sulfide and another feed component is introduced into an absorber that the feed stream flows upward from the bottom of the absorber and contacts a liquid treatment solution, where the liquid treatment solution contains a sulfur dye catalyst. The hydrogen sulfide is absorbed into the liquid treatment solution and converted into sulfide ions. The other feed component is removed from the absorber vessel substantially free of the hydrogen sulfide and a spent treatment solution is also removed from the absorber vessel and fed to an oxidation vessel where it is contacted with an oxygen containing gas causing the sulfide ions to oxidize to thiosulfate and converting the spent sulfur dye catalyst to regenerated sulfur dye catalyst. The thiosulfate is recovered, and the regenerated sulfur dye catalyst can be recycled as part of the liquid treatment solution.

A process is presented where a feed stream containing a hydrogen sulfide and another feed component is introduced into an absorber that the feed stream flows upward from the bottom of the absorber and contacts a liquid treatment solution, where the liquid treatment solution contains a sulfur dye catalyst. The hydrogen sulfide is absorbed into the liquid treatment solution and converted into sulfide ions. The other feed component is removed from the absorber vessel substantially free of the hydrogen sulfide and a spent treatment solution is also removed from the absorber vessel and fed to an oxidation vessel where it is contacted with an oxygen containing gas causing the sulfide ions to oxidize to thiosulfate and converting the spent sulfur dye catalyst to regenerated sulfur dye catalyst. The thiosulfate is recovered, and the regenerated sulfur dye catalyst can be recycled as part of the liquid treatment solution.

A method for removing sulfides from an aqueous liquid, wherein the aqueous liquid is contacted with an oxidizer in the presence of fibrous material dyed with at least one sulfur dye or sulfurized vat dye, to convert the sulfides in the aqueous liquid to a non-toxic product.

A method for removing sulfides from an aqueous liquid, wherein the aqueous liquid is contacted with an oxidizer in the presence of fibrous material dyed with at least one sulfur dye or sulfurized vat dye, to convert the sulfides in the aqueous liquid to a non-toxic product.

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum based chemotherapeutics.

In a method for the production of a fertilizer from the sulfur and ammonia content in a feed gas, including steps of (a) combustion of the H.sub.2S-rich gas in air to convert H.sub.2S to SO.sub.2, (b) formation of ammonium hydrogen sulfite (AHS) by absorption of SO.sub.2 and NH.sub.3 in water, and (c) reaction of the AHS from step (b) with H.sub.2S and NH.sub.3 to form an aqueous solution of ammonium thiosulfate (ATS), reaction (a) is carried out in a catalytic reactor as a selective oxidation of the H.sub.2S content to SO.sub.2 over a selective catalyst having one or more metal oxides, in which the metal is selected from the group of V, W, Ce, Mo, Fe, Ca and Mg, and one or more supports taken from the group of Al.sub.2O.sub.3, SiO.sub.2, SiC and TiO.sub.2, optionally in the presence of other elements in a concentration below 1 wt %.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum based chemotherapeutics.